Yingqin Hou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yingqin Hou has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Peng Wu
Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, USA
31 shared publications - Brandon Dinner
Department of Molecular and Cellular Biology, The Scripps Research Institute, La Jolla, California
30 shared publications - Evan W. Weber
Division of Oncology, Department of Pediatrics, The Children’s Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, USA
30 shared publications - Isaraphorn Pratumchai
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, California
30 shared publications - Jaroslav Zak
Huntsman Cancer Institute, University of Utah 28 Department of Radiation Oncology Salt Lake City, UT
30 shared publications - John R. Teijaro
Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, USA
30 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S6 EZH2 inhibition by tazemetostat during in vitro expansion enhanced in vivo response of OT-I cells upon LM-OVA infection and improved long-term survival of OT-I cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S6 EZH2 inhibition by tazemetostat during in vitro expansion enhanced in vivo response of OT-I cells upon LM-OVA infection and improved long-term survival of OT-I cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S2. Induction of EZH2 expression during human T cell stimulation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S2. Induction of EZH2 expression during human T cell stimulation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S1 Expression level of EZH2 in public datasets and Phenotypic analysis of effector and exhausted OT-I T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S1 Expression level of EZH2 in public datasets and Phenotypic analysis of effector and exhausted OT-I T cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S14 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S14 Phenotype and cytokine expression analysis of HA-28z CAR-T cells treated with vehicle or tazemeostat before (A-B) or after (C-D) a re-stimulation for 3 days. 3 repeats for each group (n=3), nsP > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; analyzed by Student’s t-test.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S14 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S14 Phenotype and cytokine expression analysis of HA-28z CAR-T cells treated with vehicle or tazemeostat before (A-B) or after (C-D) a re-stimulation for 3 days. 3 repeats for each group (n=3), nsP > 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; analyzed by Student’s t-test.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S8 Phenotype analysis of OT-I cells from B16-OVA tumor and EZH2 knockout provided a similar phenotype of OT-I cells as tazemetostat inhibition but impaired survival upon restimulation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S8 Phenotype analysis of OT-I cells from B16-OVA tumor and EZH2 knockout provided a similar phenotype of OT-I cells as tazemetostat inhibition but impaired survival upon restimulation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S4 OT-I splenocytes were stimulated with 500 nM OVA257-264 for 3 days in the presence of 60 IU/mL IL2 and analyzed on day3.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S4 OT-I splenocytes were stimulated with 500 nM OVA257-264 for 3 days in the presence of 60 IU/mL IL2 and analyzed on day3.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S7 Phenotype and cytokine expression analysis of OT-I cells in LM-OVA infection model
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S7 Phenotype and cytokine expression analysis of OT-I cells in LM-OVA infection model
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S9 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S8 Phenotype analysis of OT-I cells from B16-OVA tumor and EZH2 knockout provided a similar phenotype of OT-I cells as tazemetostat inhibition but impaired survival upon restimulation.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S8 Phenotype analysis of OT-I cells from B16-OVA tumor and EZH2 knockout provided a similar phenotype of OT-I cells as tazemetostat inhibition but impaired survival upon restimulation.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S11 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S11 Overlap of transcriptomic impact of Ezh2 deletion vs Taz treatment on CD8 T Cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S11 Overlap of transcriptomic impact of Ezh2 deletion vs Taz treatment on CD8 T Cells.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S5 Transient inhibition of EZH2 with tazemetostat reduces exhaustion features of antigen specific CD8+ T cells.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Transient EZH2 Suppression by Tazemetostat during In Vitro Expansion Maintains T-Cell Stemness and Improves Adoptive T-Cell Therapy
Figure S5 Transient inhibition of EZH2 with tazemetostat reduces exhaustion features of antigen specific CD8+ T cells.